Although CD34 cell dose is known to influence outcome of peripheral stem celland/or T-cell-depleted transplantation, such data on unmanipulated marrow transplantation are scarce. To study the influence of CD34 ؉ cell dose on hematopoietic reconstitution and incidence of infections after bone marrow transplantation, we retrospectively analyzed 212 patients from January 1994 to August 1999 who received a transplant of an unmanipulated graft from an HLA-identical sibling donor. Median age was 31 years; 176 patients had hematologic malignancies. Acute graft-versus-host disease prophylaxis consisted mainly in cyclosporin associated with methotrexate (n ؍ 174). Median number of bone marrow nucleated cells and CD34 ؉ cells infused were 2.4 ؋ 10 8 /kg and 3.7 ؋ 10 6 /kg, respectively. A CD34 ؉ cell dose of 3 ؋ 10 6 /kg or more significantly influenced neutrophil (hazard ratio [HR] ؍ 1.37, P ؍ .04), monocyte (HR ؍ 1.47, P ؍ .02), lymphocyte (HR ؍ 1.70, P ؍ .003), erythrocyte (HR ؍ 1.77, P ؍ .0002), and platelet (HR ؍ 1.98, P ؍ .00008) recoveries. CD34 ؉ cell dose also influenced the incidence of secondary neutropenia (HR ؍ 0.60, P ؍ .05). Bacterial and viral infections were not influenced by CD34 cell dose, whereas it influenced the incidence of fungal infections (HR ؍ 0.41, P ؍ .008). Estimated 180-day transplantation-related mortality (TRM) and 5-year survival were 25% and 56%, respectively, and both were highly affected by CD34 ؉ cell dose (HR ؍ 0.55, P ؍ .006 and HR ؍ 0.54, P ؍ .03, respectively). Five-year survival and 180-day TRM were, respectively, 64% and 19% for patients receiving a CD34 ؉ cell dose of 3 ؋ 10 6 /kg or more and 40% and 37% for the remainders. In conclusion a CD34 ؉ cell dose of 3 ؋ 10 6 /kg or more improved all hematopoietic recoveries, decreased the incidence of fungal infections and TRM, and improved overall survival.